
For research use only. We do not supply to patients.
For pharmaceutical-grade products or other inquiries, please contact our experts.
Avatrombopag is a thrombopoietin receptor agonist (TPO mimetic) which structurally resembles the endogenous ligand thrombopoietin (TPO), the key natural growth factor that regulates platelet production. Avatrombopag binds to the TPO receptor on a different site to TPO to activate downstream JAK/STAT and MAPK (ERK) signaling pathways that drive megakaryocyte proliferation and differentiation. In vitro, avatrombopag triggers concentration-dependent proliferation of TPO receptor-expressing cells (EC50 3.3 nmol/L) and megakaryocyte differentiation from CD34+ cells (EC50 25.0 nmol/L) with equivalent potency to recombinant human TPO. The compound also has additive effects with rhTPO on megakaryocyte proliferation and early progenitor cell maturation. In mouse models, avatrombopag dose-dependently increases human platelet counts in vivo. Importantly, avatrombopag increases platelet count in chronic liver disease patients, and there is no evidence of increased platelet activation and reactivity with avatrombopag treatment, in contrast to what has been hypothesized as a property of TPO to lower activation thresholds. The differential binding to the TPO receptor by avatrombopag does not impede the function of endogenous TPO.
Fig. 1 Mechanism of action of avatrombopag. (Markham A. 2021)
References
Cat NO.: INT2068065052
CAS NO.: 2068065-05-2
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
All our products are chemicals for research purposes only. We do not supply for human or veterinary applications.
Privacy Policy | Cookie Policy Copyright © Protheragen. All Rights Reserved.
